Recombinant multi-species EVA1C protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EVA1C protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Enables heparin binding activity. Colocalizes with extracellular region. [provided by Alliance of Genome Resources, Apr 2022]
The Alternative Names of target: 1700092M14Rik,4931408A02Rik,B18,B19,C1H21orf63,C21orf63,C21orf64,C31H21orf63,EVA1C,Eva1c,FAM176C,Fam176c,PRED34,Protein FAM176C,Protein eva-1 homolog C,RGD1307569,SUE21

Target products collectionGo to EVA1C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0188-Ag-1/ GM-Tg-hg-SE0188-Ag-2 Human EVA1C protein Human
GM-Tg-rg-SE0188-Ag-1/ GM-Tg-rg-SE0188-Ag-2 Rat EVA1C protein Rat
GM-Tg-mg-SE0188-Ag-1/ GM-Tg-mg-SE0188-Ag-2 Mouse EVA1C protein Mouse
GM-Tg-cynog-SE0188-Ag-1/ GM-Tg-cynog-SE0188-Ag-2 Cynomolgus/Rhesus macaque EVA1C protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0188-Ag-1/ GM-Tg-felg-SE0188-Ag-2 Feline EVA1C protein Feline
GM-Tg-cang-SE0188-Ag-1/ GM-Tg-cang-SE0188-Ag-2 Canine EVA1C protein Canine
GM-Tg-bovg-SE0188-Ag-1/ GM-Tg-bovg-SE0188-Ag-2 Bovine EVA1C protein Bovine
GM-Tg-equg-SE0188-Ag-1/ GM-Tg-equg-SE0188-Ag-2 Equine EVA1C protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0188-Ag-1/ GM-Tg-hg-SE0188-Ag-2; GM-Tg-rg-SE0188-Ag-1/ GM-Tg-rg-SE0188-Ag-2;
GM-Tg-mg-SE0188-Ag-1/ GM-Tg-mg-SE0188-Ag-2; GM-Tg-cynog-SE0188-Ag-1/ GM-Tg-cynog-SE0188-Ag-2;
GM-Tg-felg-SE0188-Ag-1/ GM-Tg-felg-SE0188-Ag-2; GM-Tg-cang-SE0188-Ag-1/ GM-Tg-cang-SE0188-Ag-2;
GM-Tg-bovg-SE0188-Ag-1/ GM-Tg-bovg-SE0188-Ag-2; GM-Tg-equg-SE0188-Ag-1/ GM-Tg-equg-SE0188-Ag-2
Products Name EVA1C protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name EVA1C
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EVA1C protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.